MarketPulse

PSMA-targeted therapy

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Telix Pharma's TLX591-Tx Clears Phase 3 Safety Hurdle, Paves Path to Expansion

Telix Pharmaceuticals' TLX591-Tx meets Phase 3 safety objectives in prostate cancer trial, advancing toward U.S. expansion with FDA.
TLXPhase 3 clinical trialFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

PYLARIFY Makes History as First Blockbuster Radiodiagnostic Amid PSMA Market Expansion

PYLARIFY becomes first radiodiagnostic to exceed $1 billion in annual sales with 24% growth, as PSMA-targeted prostate cancer treatments gain significant market momentum.
NVSLNTHPET imagingPYLARIFY